Psoriatic Arthritis News

Studies that feature work participation as an outcome in patients with inflammatory arthritis should identify key contextual factors — such as job type or social security system — upfront, according to new “points to consider” from EULAR.

Treatment with guselkumab results in higher enthesitis resolutions rates at week 24, with maintenance of those higher rates through 1 year, in patients with psoriatic arthritis, according to data published in Rheumatology.

Guselkumab is comparable to interleukin-17A and subcutaneous TNF inhibitors for efficacy, and demonstrated a better PASI response relative to other drugs, in patients with psoriatic arthritis, according to a meta-analysis published in Rheumatology.

Janus kinase inhibitors “may prove useful” in a wider range of immune-mediated inflammatory diseases, including refractory cutaneous dermatomyositis, chronic plaque psoriasis and other conditions, according to a speaker here.

Experimental studies indicate that sleep loss can lead to elevated concentrations of proinflammatory cytokines and enhance the perception of pain among patients with immune-mediated inflammatory diseases, according to a speaker here.

The combined “derm-rheum” clinic offers a unique opportunity to streamline care and improve drug access for patients with psoriatic arthritis while enhancing cross-disciplinary education among dermatologists and rheumatologists, noted a speaker at a recent summit.

Clinicians should consider the heterogeneity of psoriatic arthritis when selecting therapeutic options, according to a speaker at the ACR State-of-the-Art Clinical Symposium.

Although the overall incidence of psoriatic arthritis in the United States remained stable from 2000 to 2017, there was a 3% per-year increase among women during this time, according to data published in Arthritis & Rheumatology.

Rituximab was associated with more severe COVID-19 in patients with inflammatory rheumatic and musculoskeletal diseases, according to data published in The Lancet Rheumatology.

A daily 30 mg dose of upadacitinib — but not the 15 mg dose — is superior to adalimumab at improving the signs and symptoms of psoriatic arthritis among patients with inadequate response to non-biologic disease-modifying antirheumatic drugs.